摘要
目的:探讨急性前壁心肌梗死患者急诊经皮冠脉介入治疗(PCI)早期应用替罗非班的疗效及安全性。方法:将2009年8月至2012年12月佛山市第二人民医院收治的188例急性前壁心肌梗死拟行急诊PCI患者随机分为观察组(早期应用组,92例)和对照组(延迟应用组,96例),比较两组PCI TIMI血流分级、血BNP、CTnI水平变化及主要不良心血管事件和出血风险等。结果:观察组初次造影病变血管TIMI血流达到Ⅲ级的比率明显高于延迟应用组(P<0.05);术后7 d血CTnI、BNP水平明显低于对照组(P<0.05);30 d不良心血管事件发生率低于对照组(P<0.05)。结论:急性前壁心肌梗死患者急诊PCI早期应用替罗非班有助于改善心肌灌注,降低早期不良心血管事件,可能有助于改善远期预后。
Objective: To investigate the efficacy and safety of tirofiban on early-stage acute anterior myocardial infarction via percutaneous coronary intervention (PCI). Methods: We randomly allocated 188 patients with acute anterior myocardial infarction who were admitted to Foshan Second People' s Hospital between August 2009 and December 2012 to be treated with tirofiban therapy during early stage (observational group, n = 92 ) and in a delayed manner ( control group, n= 96). This entailed comparison on the TIMI blood flow grading, changes in the level of cTnI, major cardiovascular adverse events and the risk of bleeding. Results: The observational group was associated with a pronouncedly higher proportion of patients with grade Ⅲ TIMI blood flow and yielded markedly lower levels of serum cTnI and brain natriuretic peptide at day 7 than control group ( all P 〈 0.05). A significantly lower incidence of cardiovascular adverse events was noted in observational group at day 30 ( P 〈 0.05 ). Conclusion: Administration of tirofiban at an early-stage is effective in improving the myocardial blood perfusion, reducing the early-stage cardiovascular adverse events and might improve long-term prognosis in patients with acute anterior myocardial infarction.
出处
《广州医学院学报》
2013年第6期51-54,共4页
Academic Journal of Guangzhou Medical College